Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Ariya Bio

Company Type: Therapeutics

Main focus: Development of genome editing therapies for haemoglobinopathies

Company stage: Pre-clinical

Diseases: Haemoglobinopathies

Genome-editing tool: CRISPR-Cas

Funding stage: Pre-seed

Location: Schlieren, Switzerland

Website: https://www.ariyabio.ch/

Pipeline:

Partners:

Ariya Bio is a pre-clinical stage company that focuses on developing new CRISPR-based cell and gene therapies for hereditary blood diseases. Their current programmes are focused on beta-haemoglobinopathies and alpha-thalassemia.

Tags

HashtagARIYA BIO

Company: Ariya Bio
close
Search CRISPR Medicine